SAN CLEMENTE, Calif., Sept. 1, 2006 (PRIMEZONE) -- There is a growing worldwide demand for more efficacious pharmaceutical agents to combat glaucoma and age-related macular degeneration. In addition, there is demand for more critical and accurate medical devices for the detection and removal of cataracts. The Company's effort to respond with cost effective and novel solutions has garnered significant attention from European investors.
Accordingly, ART engaged the services of Florencia Mate Garobito. After extensive due diligence, the Company, jointly, concluded that a listing on the Frankfurt Stock Exchange was desirable. The Company applied for and was accepted for trading on the Frankfurt Stock Exchange on August 30, 2006 under the symbol B6W.
ART's trading activity in Europe can be followed on the worldwide web at www.comdirect.de (go to kurssuche -- upper left and change it to B6W).
On another note, Randy Bailey, CEO and President, has been interviewed by both the "Wall Street Reporter" and "WallSt.net." A comprehensive and succinct overview of his vision and strategy for ART's continued involvement in the ophthalmic market is provided in both of these interviews.
The interview on "Wall Street Reporter" is linked to the ART website www.advancedrefractive.com. The interview by "WallSt.net" can be accessed on the interview section of their website at www.wallst.net.
About Advanced Refractive Technologies, Inc.
Advanced Refractive Technologies, Inc. is an ophthalmology development company focused on the development and marketing of innovative ophthalmic applications that will result in faster, safer and more effective procedures in two of the largest surgical markets in the world: corrective refractive surgery and cataract surgery, as well as innovative drugs for glaucoma and age-related macular degeneration. Advanced Refractive Technologies is currently in the process of developing their Accupulse, a next generation cataract emulsifier, which utilizes the company's proprietary waterjet technology. The Accupulse cataract emulsifier, currently under development, is a device that uses pulsed waterjet technology to remove cataracts -- the most frequently performed surgical procedure in the world. For more information on Advanced Refractive Technologies, please visit its website at http://www.advancedrefractive.com.
The Advanced Refractive Technologies, Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2498